Supplementary Figure 2 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Kaushik Varadarajan; Christian X. Cruz Pico; Kurt W. Evans; Maria Gabriela Raso; Yasmeen Q. Rizvi; Xiaofeng Zheng; Dhruv Chachad; Timothy P. DiPeri; Bailiang Wang; Stephen M. Scott; Ming Zhao; Argun Akçakanat; Antje M. Wengner; Timothy A. Yap; Funda Meric‐Bernstam

doi:10.1158/1535-7163.30028672

September 2, 2025Open Access

Supplementary Figure 2 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

View Full Paper

Ask AI

Bookmark

Share

Key Points

This analysis shows the tumor volume growth curve in models treated with ATR kinase inhibitors like elimusertib.
The waterfall plots illustrate the treatment effects observed by day 20 in the control group versus treatment groups.
Observational analysis includes comparing tumor responses in models exhibiting DNA damage response and genomic alterations.
These findings may inform future studies on optimizing therapies for tumors with specific genetic vulnerabilities.

Implication

Analysis shows tumor volume growth in models treated with ATR kinase inhibitor, highlighting its effects on DNA damage response.

Abstract

Supplementary Figure 2. Tumor volume growth curve and waterfall plots for models shown in Figure 1. Waterfall plot represent day 20 or the last day of control group measurement.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Varadarajan et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02a00 https://doi.org/10.1158/1535-7163.30028672

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 2 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 2 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading